Stockscreener 앱 받기
24.38
2.05%
-0.46
시간 외 거래:
24.40
0.02
+0.08%
전일 마감가:
$24.84
열려 있는:
$24.88
하루 거래량:
383.35K
Relative Volume:
0.79
시가총액:
$1.08B
수익:
$10.32M
순이익/손실:
$-89.93M
주가수익비율:
-10.13
EPS:
-2.4064
순현금흐름:
$-88.63M
1주 성능:
-0.73%
1개월 성능:
+54.97%
6개월 성능:
+63.18%
1년 성능:
+482.06%
1일 변동 폭
$23.39
$24.93
1주일 범위
$23.39
$25.95
52주 변동 폭
$4.11
$25.95
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
24.39 | 1.10B | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Needham | Buy |
| 2026-02-25 | 개시 | Oppenheimer | Outperform |
| 2026-02-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-01-27 | 개시 | Piper Sandler | Overweight |
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge advances inflammaging drug into Phase 2 - Longevity.Technology
Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Frau - GuruFocus
Bioage Labs stock hits 52-week high at 25.8 USD - Investing.com
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Sahm
Form 4 Bioage Labs Inc For: 1 July By Investing.com - Investing.com Nigeria
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: - GuruFocus
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing - Moomoo
BioAge Labs principal accounting officer sells $1.57m in stock - Investing.com
BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com - Investing.com South Africa
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (BIOA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Biotech Development StageMid-Term Outlook - dars.gov.et
BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale - Stock Titan
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Yahoo Finance
Form 144 BioAge Labs For: 29 June By Investing.com - Investing.com Nigeria
BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000E Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBIT forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically? - Sahm
BioAge Labs, Inc. Actuals & Estimates (NASDAQ:BIOA) - TradingView
BIOAGE Labs Inc (BIOA) Institutional Confidence - TradingKey
BioAge Labs, Inc. Actuals & Estimates (GETTEX:Y7G) - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
Bioage Labs stock hits 52-week high at 24.03 USD By Investing.com - Investing.com Australia
Bioage Labs stock hits 52-week high at 24.03 USD - Investing.com UK
Enterprise value to revenue forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
Price to earnings forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
BIOA Forecast — Price Target — Prediction for 2027 - TradingView
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor - Yahoo Finance
BioAge Labs: Developing A 'Pipeline In A Pill' (NASDAQ:BIOA) - Seeking Alpha
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BIOAGE Labs Inc (BIOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pend - GuruFocus
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Maintains Target Price $23 - Moomoo
BIOAGE Labs Inc (BIOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIOAGE Labs Inc (BIOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioAge doses first patient in phase 2 cardiovascular trial - Investing.com
BioAge doses first patient in phase 2 cardiovascular trial By Investing.com - Investing.com South Africa
BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102 for Cardiovascular Risk - marketscreener.com
Bioage Labs Inc (BIOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bioage Labs Inc 주식 (BIOA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer |
Jun 30 '26 |
Option Exercise |
6.53 |
20,216 |
132,017 |
20,216 |
| Barton Shane | Principal Accounting Officer |
Jun 29 '26 |
Sale |
25.21 |
42,350 |
1,067,576 |
0 |
| Barton Shane | Principal Accounting Officer |
Jun 30 '26 |
Sale |
25.19 |
20,216 |
509,176 |
0 |
0.15%
1.83%
자본화:
|
볼륨(24시간):